Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott R Plotkin

Showing results (121-130 of 201) with videos related to

Pageof 21
Sort By:
Contemporary Clinical Trials|August 29, 2022
Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related painJennifer L W Da, Vanessa L Merker, Justin T Jordan, et al.
Neurology|August 1, 2023
Association of <i>MTHFR</i> Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based RegimensPhilipp Karschnia, Sylvia C Kurz, Priscilla K Brastianos, et al.
Oncotarget|July 30, 2015
A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomasRoberta L Beauchamp, Marianne F James, Patrick A DeSouza, et al.
Developmental Medicine and Child Neurology|December 5, 2012
Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approachAgnies M van Eeghen, Margaret B Pulsifer, Vanessa L Merker, et al.
Journal of Neuro-Oncology|May 12, 2009
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannomaScott R Plotkin, Chris Halpin, Jaishri O Blakeley, et al.
Oncotarget|March 19, 2015
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancerDavid M Jackman, Leigh A Cioffredi, Lorraine Jacobs, et al.
Plos One|May 5, 2012
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosisScott R Plotkin, Miriam A Bredella, Wenli Cai, et al.
Neurology|July 7, 2021
Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical TrialsAshley Cannon, Dominique C Pichard, Pamela L Wolters, et al.
Neuro-Oncology|February 22, 2023
Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannomaSrirupa Bhattacharyya, Janet L Oblinger, Roberta L Beauchamp, et al.
Clinical Trials (London, England)|November 8, 2023
Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trialsVerena Staedtke, Kara Anstett, David Bedwell, et al.
Pageof 21

Showing results (121-130 of 201) with videos related to

Sort By:
Pageof 21
Contemporary Clinical Trials|August 29, 2022
Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related painJennifer L W Da, Vanessa L Merker, Justin T Jordan, et al.
Neurology|August 1, 2023
Association of <i>MTHFR</i> Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based RegimensPhilipp Karschnia, Sylvia C Kurz, Priscilla K Brastianos, et al.
Oncotarget|July 30, 2015
A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomasRoberta L Beauchamp, Marianne F James, Patrick A DeSouza, et al.
Developmental Medicine and Child Neurology|December 5, 2012
Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approachAgnies M van Eeghen, Margaret B Pulsifer, Vanessa L Merker, et al.
Journal of Neuro-Oncology|May 12, 2009
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannomaScott R Plotkin, Chris Halpin, Jaishri O Blakeley, et al.
Oncotarget|March 19, 2015
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancerDavid M Jackman, Leigh A Cioffredi, Lorraine Jacobs, et al.
Plos One|May 5, 2012
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosisScott R Plotkin, Miriam A Bredella, Wenli Cai, et al.
Neurology|July 7, 2021
Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical TrialsAshley Cannon, Dominique C Pichard, Pamela L Wolters, et al.
Neuro-Oncology|February 22, 2023
Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannomaSrirupa Bhattacharyya, Janet L Oblinger, Roberta L Beauchamp, et al.
Clinical Trials (London, England)|November 8, 2023
Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trialsVerena Staedtke, Kara Anstett, David Bedwell, et al.
Pageof 21